Dementias & Alzheimer’s

In Vitro Diagnostic Test for Alzheimer’s Disease Receives Marketing Authorization

The Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic is an FDA-authorized test to aid in the assessment of Alzheimer’s disease.

Dementias & Alzheimer’s

Diadem’s Early Alzheimer’s Prediction Test Gets CE-IVD Certification

Diadem Srl today announced CE IVD certification for its AlzoSure Predict prognostic blood test for the early prediction of Alzheimer's disease.

Dementias & Alzheimer’s

An Alzheimer’s Disease Risk Factor May Predispose Carriers to Severe COVID-19

Researchers have reported observations that show a link between APOE4 and COVID-19, in terms of susceptibility to SARS-CoV-2 infection and mortality.

Researchers Investigate if APOE4 Gene Key to Alzheimer’s

Sep 17, 2021 | Dementias & Alzheimer’s

Daegu Gyeongbuk Institute of Science and Technology researchers investigated if the APOE4 gene in astrocytes relates to Alzheimer’s disease.

Dementia Risk Pinpointed in Blood Metabolites

Sep 13, 2021 | Dementias & Alzheimer’s, Uncategorized

Scientists in Japan have identified metabolic compounds within the blood that are associated with dementia.

Biomarker Test May Predict Alzheimer’s 6 Years Before Diagnosis

Aug 27, 2021 | Dementias & Alzheimer’s

Diadem srl has announced results from a retrospective longitudinal study of its AlzoSure Predict prognostic biomarker test for Alzheimer’s.

Genetic Marker Identifies Common Change in FTLD and ALS Patients

Aug 23, 2021 | Dementias & Alzheimer’s

A novel genetic tool has been discovered to identify C9orf72 in FTLD or ALS patients from large population-based cohorts.

15 New Biomarkers Linked to Late-Onset Dementia

Aug 3, 2021 | Dementias & Alzheimer’s

A study by an international research group identified 15 novel biomarkers that are linked to late-onset dementias.

Biomarkers Can Detect Alzheimer’s in Living Patients

Jul 20, 2021 | Dementias & Alzheimer’s

Alzheimer’s disease can be accurately identified in living patients by collecting cerebrospinal fluid using a framework of three biomarkers.

Diagnosing Neurodegeneration May Be a Blood Test Away

Jun 7, 2021 | Dementias & Alzheimer’s

Levels of NfL in the blood can identify those who might have neurodegenerative diseases when clinical symptoms are not definitive.

PreADx Alzheimer’s Detection Immunoassay Proof of Concept Study Successful

Mar 31, 2021 | Dementias & Alzheimer’s, Immunoassay

Unlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes.

Detecting Alzheimer’s Gets Easier with a Simple Blood Test

Feb 4, 2021 | Dementias & Alzheimer’s, Mass Spectrometry

Blood tests show promise in diagnosing Alzheimer’s with less cost and less burdensome procedures, and could be used to identify patients for trials of potential drugs, reports Scientific American.

New Studies Support Blood Test for Early Detection of Alzheimer’s

Jan 17, 2021 | Dementias & Alzheimer’s, Research

Rresearchers provide convincing evidence that an in-house developed blood test for Alzheimer’s disease can detect the disease early and track its course, which has major implications for a potential use in clinical practice and treatment trials.

Prognostic Alzheimer’s Disease Blood Test in Symptom-Free Stage

Jan 8, 2021 | Dementias & Alzheimer’s, Research

Using a blood test, a research team has predicted the risk of Alzheimer’s disease in people who were clinically diagnosed as not having Alzheimer’s disease but who perceived themselves as cognitively impaired.

Potential New Ways to Identify Early Changes in Alzheimer’s Disease

Dec 14, 2020 | Dementias & Alzheimer’s, Diagnostic Technologies, Research

Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer’s disease before cognitive problems develop.

Fujirebio Files for FDA 510(K) for Alzheimer’s Diagnostic

Dec 4, 2020 | Dementias & Alzheimer’s

When cleared, the FDA-designated breakthrough device is expected to be among the first commercially available in vitro diagnostics for patients being evaluated for Alzheimer’s disease in the United States.